Anti-diabetic and anti-proliferative activities of herbal teas, Athrixia phylicoides DC and Monsonia burkeana Planch. ex Harv, indigenous to South Africa

2019 ◽  
Vol 121 (4) ◽  
pp. 964-974 ◽  
Author(s):  
Lutendo Patricia Mathivha ◽  
Vuyisile Samuel Thibane ◽  
Fhatuwani Nixwell Mudau

Purpose The purpose of this paper is to investigate the health and medicinal importance of bush tea (Athrixia phylicoides DC) and special tea (Monsonia burkeana Planch. ex Harv), two of Southern African indigenous herbal teas. Design/methodology/approach The two herbal teas, A. phylicoides and M. burkeana were extracted individually and in combined ratios for analysis. The phenolic content was determined and the different phenolic compounds were identified using thin-layer chromatography (TLC) and high-performance liquid chromatography (HPLC). The anti-diabetic activity of the teas was determined by evaluating the inhibition of both α-amylase and α-glucosidase in vitro. The anti-proliferative activity was measured on human cervical cancer (HeLa) cell line using the MTT (3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium) assay. Findings Gallic acid, chlorogenic acid and quercetin were identified to be present in significant quantities by TLC. The HPLC quantified the presence of catechin (1.567 mg/g) and chlorogenic acid (1.862 mg/g) in special tea while chlorogenic acid (1.288 mg/g) was present in bush tea. Bush tea and special tea expressed significant levels of phenolic content and high antioxidant activities. Special tea (S100) expressed high inhibition of α-amylase, α-glucosidase and HeLa cell line proliferation when compared to bush tea (B100). Originality/value Both bush tea and special tea could provide an alternative for treatment and management of both diabetes and cervical cancer. However, future studies are needed to investigate their synergistic effect with a wide range of other commercial herbal teas.

2020 ◽  
Vol 16 ◽  
Author(s):  
Jamshed Iqbal ◽  
Ayesha Basharat ◽  
Sehrish Bano ◽  
Syed Mobasher Ali Abid ◽  
Julie Pelletier ◽  
...  

Aims: The present study was conducted to examine the inhibitory effects of synthesized sulfonylhydrazones on the expression of CD73 (ecto-5′-NT). Background: CD73 (ecto-5′-NT) represents the most significant class of ecto-nucleotidases which are mainly responsible for dephosphorylation of adenosine monophosphate to adenosine. Inhibition of CD73 played an important role in the treatment of cancer, autoimmune disorders, precancerous syndromes, and some other diseases associated with CD73 activity. Objective: Keeping in view the significance of CD73 inhibitor in the treatment of cervical cancer, a series of sulfonylhydrazones (3a-3i) derivatives synthesized from 3-formylchromones were evaluated. Methods: All sulfonylhydrazones (3a-3i) were evaluated for their inhibitory activity towards CD73 (ecto-5′-NT) by the malachite green assay and their cytotoxic effect was investigated on HeLa cell line using MTT assay. Secondly, most potent compound was selected for cell apoptosis, immunofluorescence staining and cell cycle analysis. After that, CD73 mRNA and protein expression were analyzed by real-time PCR and Western blot. Results: Among all compounds, 3h, 3e, 3b, and 3c were found the most active against rat-ecto-5′-NT (CD73) enzyme with IC50 (µM) values of 0.70 ± 0.06 µM, 0.87 ± 0.05 µM, 0.39 ± 0.02 µM and 0.33 ± 0.03 µM, respectively. These derivatives were further evaluated for their cytotoxic potential against cancer cell line (HeLa). Compound 3h and 3c showed the cytotoxicity at IC50 value of 30.20 ± 3.11 µM and 86.02 ± 7.11 µM, respectively. Furthermore, compound 3h was selected for cell apoptosis, immunofluorescence staining and cell cycle analysis which showed promising apoptotic effect in HeLa cells. Additionally, compound 3h was further investigated for its effect on expression of CD73 using qRT-PCR and western blot. Conclusion: Among all synthesized compounds (3a-3i), Compound 3h (E)-N'-((6-ethyl-4-oxo-4H-chromen-3-yl) methylene)-4-methylbenzenesulfonohydrazide was identified as most potent compound. Additional expression studies conducted on HeLa cell line proved that this compound successfully decreased the expression level of CD73 and thus inhibiting the growth and proliferation of cancer cells.


2020 ◽  
pp. 4-7
Author(s):  
M. R. Kamala Priya ◽  
Priya R. Iyer

Doxorubicin is the most common chemotherapy drug used in cancer therapy. Its usage is associated with various side-effects. In order to overcome the challenges in Doxorubicin administration, the present study has focussed on synthesizing a drug conjugate with biosynthesized gold nanoparticles and doxorubicin. The gold nanoparticles were biosynthesized using green extracts of medicinal plants with potential anticancer activities. The nanoparticle that possesses anticancer activity was conjugated with the drug for a combinatorial effect of the nanoparticles and the drug. The in vitro cytotoxicity was checked in Vero cell line through MTT assay. The in vitro anti proliferative effects were screened against cervical cancer in HeLa cell line. Fluorescence activated cell sorting analysis was carried out to detect the difference between live and dead cell populations. The preliminary confirmation was carried out in UV-VIS spectrophotometer. The morphological characterization was carried out by SEM and stability by Zeta potential. The IC50 of the nanocompounds demonstrated anti-proliferative activity against cervical cancer similar to the chemotherapeutic drug, Doxorubicin; additionally in a much lesser concentration of the drug. The in vitro cytotoxicity exhibited high viability of cells in Vero cell line with minimum viability of 80% in all the tested concentrations. There was a synergistic effect of the nanoparticles along with the drug; thereby an enhanced therapeutic efficiency was achieved. FACS analysis showed 36% of cell death in Dox treated HeLa cells whereas 96% of cell death in Nano-Dox treated HeLa cells. Nano-Dox conjugate has demonstrated high anticancer effects than drug alone Doxorubicin. Further biosynthesized nanomaterials based drug formulation can be developed as a potential strategy in cancer therapy.


2020 ◽  
Vol 47 (8) ◽  
pp. 6135-6142
Author(s):  
Jalal Hassanshahi ◽  
Afsaneh Mirzahosseini-pourranjbar ◽  
Zahra Hajializadeh ◽  
Ayat Kaeidi

2017 ◽  
Vol 24 (4) ◽  
pp. 563-570 ◽  
Author(s):  
Hannaneh Zarrinnahad ◽  
Amir Mahmoodzadeh ◽  
Monireh Parviz Hamidi ◽  
Mehdi Mahdavi ◽  
Ali Moradi ◽  
...  

Toxicology ◽  
2009 ◽  
Vol 257 (1-2) ◽  
pp. 80-85 ◽  
Author(s):  
Hua-Nan Li ◽  
Fei-Fei Nie ◽  
Wei Liu ◽  
Qin-Sheng Dai ◽  
Na Lu ◽  
...  

Nutrients ◽  
2017 ◽  
Vol 9 (8) ◽  
pp. 798 ◽  
Author(s):  
Sandra Salazar-Aguilar ◽  
Lucero Ruiz-Posadas ◽  
Jorge Cadena-Iñiguez ◽  
Marcos Soto-Hernández ◽  
Edelmiro Santiago-Osorio ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document